Keep up to date on the newest research and clinical application of immunotherapy treatments in colorectal cancer with leading experts Dr Benjamin Schlechter and Marwan Fakih. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986437). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Colorectal Cancer https://www.medscape.com/viewarticle/776784 Microsatellite Instability in Colorectal Cancer: Overview of Its Clinical Significance and Novel Perspectives https://pubmed.ncbi.nlm.nih.gov/30543589/ PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer https://pubmed.ncbi.nlm.nih.gov/35660797/ Dostarlimab: The Miracle Drug for the Treatment of Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/36060435/ Neoadjuvant Immunotherapy Leads to Pathological Responses in MMR-Proficient and MMR-Deficient Early-Stage Colon Cancers https://pubmed.ncbi.nlm.nih.gov/32251400/ Lynch Syndrome https://www.ncbi.nlm.nih.gov/books/NBK431096/ Optimal Management of Low Anterior Resection Syndrome: Colorectal Cancer (Update) https://pubmed.ncbi.nlm.nih.gov/32730011/ Pembrolizumab (Rx) https://reference.medscape.com/drug/keytruda-pembrolizumab-999962 Carcinomatosis https://www.cancer.gov/publications/dictionaries/cancer-terms/def/carcinomatosis Association of Tumour Mutational Burden With Outcomes in Patients With Advanced Solid Tumours Treated With Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study https://pubmed.ncbi.nlm.nih.gov/32919526/ Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High or Mismatch Repair-Deficient Metastatic Colorectal Cancer (KEYNOTE-177): Final Analysis of a Randomised, Open-Label, Phase 3 Study https://pubmed.ncbi.nlm.nih.gov/35427471/ Circulating Tumor DNA Test May Help Guide GI Cancer Management https://www.medscape.com/viewarticle/982900 Durvalumab and Tremelimumab Combination Therapy Versus Durvalumab or Tremelimumab Monotherapy for Patients With Solid Tumors: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/32664183/ FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial https://pubmed.ncbi.nlm.nih.gov/34970487/ Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/34196693/ Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/36892833/ Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603) https://pubmed.ncbi.nlm.nih.gov/32343640/ Regorafenib Plus Nivolumab in Patients With Mismatch Repair-Proficient/Microsatellite Stable Metastatic Colorectal Cancer: A Single-Arm, Open-Label, Multicentre Phase 2 Study https://pubmed.ncbi.nlm.nih.gov/37090438/ CTLA-4 Cytotoxic T-Lymphocyte Associated Protein 4 [Homo sapiens (human)] https://www.ncbi.nlm.nih.gov/gene/1493 iRECIST: Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics https://pubmed.ncbi.nlm.nih.gov/28271869/ Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer https://clinicaltrials.gov/ct2/show/NCT03860272 A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer https://clinicaltrials.gov/ct2/show/NCT05608044

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related